| Author | Topic | Link to post |
|---|---|---|
| EFSPI | Strategic priorities from industry and regulators | link |
| EFSPI | Adaptive Designs for Clinical Trials | link |
| EFSPI | From Trials to Target Populations: Extending Evidence for Decision-Making | link |
| EFSPI | Anniversary session | link |
| EFSPI | Short topic session | link |
| EFSPI | From Black Box to Pandora’s Box: Navigating AI in Clinical Trials | link |
| EFSPI | Characterizing the Effect of Treatment Using Hierarchical Composite Endpoints – Risks and Benefits of Win Statistics and Beyond | link |
| EFSPI | Keeping it Real or Losing Control? Adventures in Target Trial Emulation (TTE) | link |
| EFSPI | The Added Value of Bayesian Methods for Pivotal Clinical Trials – Just a Communication Issue? | link |
| EFSPI | How to Deal with Assumptions in Drug Development? What Insights Can We Gain from ICH M15? | link |
| EFSPI | Workshop wrap-up | link |
| Kaspar Rufibach | Thank you to the local organizing committee | link |
| Fred Sorenson | HTA posters | link |
Linkedin posts reflecting on 2025 workshop
To get an idea about the special spirit of the workshop we link a few linkedin posts reflecting on the 2024 issue.
Questions?
For feedback and questions send an email to Vivian Lanius.